标题
Dapagliflozin: A Review in Type 2 Diabetes
作者
关键词
-
出版物
DRUGS
Volume 79, Issue 10, Pages 1135-1146
出版商
Springer Science and Business Media LLC
发表日期
2019-06-25
DOI
10.1007/s40265-019-01148-3
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis
- (2019) H. Hussein et al. DIABETIC MEDICINE
- Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Prior Myocardial Infarction: A Sub-analysis From DECLARE TIMI-58 Trial
- (2019) Remo H. M. Furtado et al. CIRCULATION
- Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
- (2019) Eri T. Kato et al. CIRCULATION
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes
- (2018) Dirk Müller-Wieland et al. DIABETES OBESITY & METABOLISM
- Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study
- (2018) Gian Paolo Fadini et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study
- (2018) Paola Fioretto et al. DIABETES OBESITY & METABOLISM
- A Randomized Clinical Trial of the Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in Patients with Type 2 Diabetes Mellitus and Mild Renal Insufficiency: The CompoSIT-R Study
- (2018) Russell Scott et al. DIABETES OBESITY & METABOLISM
- DECLARE-TIMI 58: Participants’ baseline characteristics
- (2018) Itamar Raz et al. DIABETES OBESITY & METABOLISM
- Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
- (2018) Beatrice C. Lupsa et al. DIABETOLOGIA
- SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
- (2018) Subodh Verma et al. DIABETOLOGIA
- SGLT-2 Inhibitors and Cardiovascular Risk
- (2018) Matthew A. Cavender et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
- (2018) Mikhail Kosiborod et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
- (2018) Eugene Han et al. Diabetes Therapy
- Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
- (2018) Eugene Han et al. Diabetes Therapy
- Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials
- (2018) Clifford J. Bailey et al. DIABETES OBESITY & METABOLISM
- SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice
- (2018) John Wilding et al. Diabetes Therapy
- Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes
- (2018) A.J. Scheen DIABETES & METABOLISM
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
- (2018) DIABETES CARE
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes
- (2018) Yehuda Handelsman et al. DIABETES OBESITY & METABOLISM
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure
- (2017) Mikhail Kosiborod et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
- (2017) Kåre I Birkeland et al. Lancet Diabetes & Endocrinology
- Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis
- (2016) Christian Sonesson et al. Cardiovascular Diabetology
- Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease
- (2016) L. A. Leiter et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes
- (2016) C. Mathieu et al. DIABETES OBESITY & METABOLISM
- Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies
- (2016) Paola Fioretto et al. DRUGS & AGING
- Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C
- (2016) Neil Skolnik et al. POSTGRADUATE MEDICINE
- Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study
- (2016) Michael A Weber et al. Lancet Diabetes & Endocrinology
- Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
- (2016) Juan P Frías et al. Lancet Diabetes & Endocrinology
- Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin–angiotensin system blockade
- (2015) Michael A. Weber et al. BLOOD PRESSURE
- Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension
- (2015) William T. Cefalu et al. DIABETES CARE
- Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes
- (2015) Chantal Mathieu et al. DIABETES CARE
- Dapagliflozin Improves Glycemic Control and Reduces Body Weight as Add-on Therapy to Metformin Plus Sulfonylurea: A 24-Week Randomized, Double-Blind Clinical Trial
- (2015) Stephan Matthaei et al. DIABETES CARE
- Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes
- (2015) S. Matthaei et al. DIABETES OBESITY & METABOLISM
- Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
- (2015) Ele Ferrannini et al. EUROPEAN HEART JOURNAL
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a ‘Case Study’
- (2015) Agata Ptaszynska et al. Diabetes Therapy
- Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a ‘Case Study’
- (2015) Agata Ptaszynska et al. Diabetes Therapy
- Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence
- (2014) A.J. Scheen et al. DIABETES & METABOLISM
- Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial
- (2014) C. J. Bailey et al. DIABETIC MEDICINE
- Dapagliflozin: A Review of Its Use in Patients with Type 2 Diabetes
- (2014) Greg L. Plosker DRUGS
- Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
- (2014) André J. Scheen DRUGS
- Dapagliflozin Added to Usual Care in Individuals with Type 2 Diabetes Mellitus with Preexisting Cardiovascular Disease: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with a 28-Week Extension
- (2014) Lawrence A. Leiter et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
- (2013) J. Bolinder et al. DIABETES OBESITY & METABOLISM
- Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
- (2013) Donald E. Kohan et al. KIDNEY INTERNATIONAL
- Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin
- (2012) Ö. Ljunggren et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin
- (2012) Greg L. Plosker DRUGS
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
- (2010) Clifford J Bailey et al. LANCET
- Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
- (2009) B Komoroski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
- (2008) Wei Meng et al. JOURNAL OF MEDICINAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started